April 20, 2018 / 5:21 AM / 5 months ago

BRIEF-Novartis says EXPAND study shows siponimod's (Baf312) efficacy

April 20 (Reuters) - Novartis AG says:

* EXPAND study showed siponimod (BAF312) reduced the risk of disability progression largely disassociated from relapses in patients with secondary progressive multiple sclerosis

* In EXPAND, siponimod also had a meaningful benefit on patients' cognitive processing speed Further company coverage: (Reporting By Zurich newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below